The Pharmaceutical Industry: Access and OutlookNova Publishers, 2002 - 193페이지 Politicians consistently wage high-profile battles over prescription drugs and the companies that make them. The dilemma is balancing the pharmaceutical industry's need to make a profit with the public's need for affordable medical care. This book presents analyses of the federal government's regulation of the drug industry and the arguments over the prices of prescription drugs. |
목차
| 1 | |
| 23 | |
Prescription Drugs Factors Influencing Their Pricing | 35 |
Prescription Drug Price Comparisons The United States Canada and Mexico | 45 |
Prescription Drugs Importation for Personal Use | 51 |
Prescription Drug Prices The Effects of Generics Formularies and Other Market Changes | 59 |
Outpatient Prescription Drugs Acquisition and Reimbursement Policies under Selected Federal Programs | 65 |
The US Drug Approval Process A Primer | 71 |
Health Care Reform and Investment in New Drug Development | 113 |
Drug Prices and the CPI | 137 |
GATT and the Pharmaceutical Industry Prospective Effects of the Uruguay Round on the Industry | 141 |
Background | 147 |
Growth in RD Investment | 151 |
Discovery and Development | 157 |
Pharmaceutical Expenditures in Perspective | 171 |
The Growth of Managed Care | 181 |
자주 나오는 단어 및 구문
103rd Congress addition agency approval process approved drugs average biological Boston Consulting Group brand-name drugs breakthrough drugs buyers clinical trials coverage CPI-U disease dispensed dosage Drug Administration drug approval drug benefit drug companies drug development drug discovery drug manufacturers drug's evaluate FDA approval FDA's Federal Food and Drug formularies funded Grabowski Health and Human health care reform health insurance health-care HMOs hospitals Ibid incentives increase investment labeling Lotronex managed managed care Medicaid Medicare medicines million outpatient prescription drugs patients percent pharmaceutical companies pharmaceutical industry pharmaceutical manufacturers pharmaceutical R&D Pharmaceutical Research pharmacies phase PhRMA physicians preclinical prescription drug prices prescription drugs Price Competition proposals proteins R&D cost rebates regulations regulatory research-based result retail risks safety and effectiveness safety and efficacy side effects testing therapeutic therapies treatment U.S. Congress U.S. Pharmaceuticals uninsured consumers United
인기 인용구
3 페이지 - Formulary, or any supplement to any of them ; and (2) articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals; and (3) articles (other than food) intended to affect the structure or any function of the body of man or other animals...
74 페이지 - drug," as used in this Act, shall include all medicines and preparations recognized in the United States Pharmacopoeia or National Formulary for internal or external use, and any substance or mixture of substances intended to be used for the cure, mitigation, or prevention of disease of either man or other animals. The term "food...
4 페이지 - As used in this subsection and subsection (e), the term "substantial evidence" means evidence consisting of adequate and well-controlled investigations, including clinical investigations, by experts qualified by scientific training and experience to evaluate the effectiveness of the drug involved, on the basis of which it could fairly and responsibly be, concluded by such experts that the drug will have the effect it purports or is represented to have under the conditions of use prescribed, recommended,...
4 페이지 - Unless its labeling bears (1) adequate directions for use; and (2) such adequate warnings against use in those pathological conditions or by children where its use may be dangerous to health, or against unsafe dosage or methods or duration of administration or application, in such manner and form, as are necessary for the protection of users...
4 페이지 - labeling" means all labels and other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such article.
75 페이지 - Secretary pursuant to subsection (b), do not include adequate tests by all methods reasonably applicable to show whether or not such drug is safe for use under the conditions prescribed, recommended, or suggested in the proposed labeling thereof...
81 페이지 - ... the rate and extent to which the active ingredient or active moiety is absorbed from a drug product and becomes available at the site of action.
72 페이지 - Congressional enactment of the Drug Price Competition and Patent Term Restoration Act of 1984 (PL 98-417).
74 페이지 - drug' means (1) articles recognized in the official United States Pharmacopoeia, official Homeopathic Pharmacopoeia of the United States, or official National Formulary, or any supplement to any of them...
4 페이지 - If in package form unless it bears a label containing (1) the name and place of business of the manufacturer, packer, or distributor; and (2) an accurate statement of the quantity of the contents in terms of...